ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch
ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch
ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces its official launch. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (“CGT”).
ViroCell aims to be the supplier of choice for viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials. ViroCell has assembled the UK’s most experienced viral vector manufacturing team to support its heavy operational demand and is now building out further manufacturing capability to a
FDA OKs Landmark Bluebird Bio, Bristol Myers Blood Cancer Therapy | North Carolina Biotechnology Center
ncbiotech.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ncbiotech.org Daily Mail and Mail on Sunday newspapers.
U S Food and Drug Administration Approves Bristol Myers Squibb s and bluebird bio s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma Seite 1
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
WALTHAM, Mass., March 1, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. This indication has been granted under accelerated approval based upon the HORIZON trial. PEPAXTO is the first anticancer peptide-drug conjugate approved in multiple myeloma.
Oncopeptides obtains FDA nod for Pepaxto
drugstorenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from drugstorenews.com Daily Mail and Mail on Sunday newspapers.